Celine Maeder

Cairn Biosciences, Inc.

$323,750

Attributed

$323,750

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$323,750 · 1

By mechanism

R44$323,750 · 1

Top collaborators

No co-investigators on record.

Most similar at Cairn Biosciences, Inc.

Same institution · by research overlap

Mary Ludlam$5,791,305

Others in their field

Other Emerging Leaders on “Analgesics”

Jeffrey Reich · Sparian Biosciences, Inc.$13,729,307
Cecile Feldman · Rbhs-School Of Dental Medicine$11,278,781
Bryan L McLaughlin · Micro-Leads, Inc.$10,201,646
James N Campbell · Centrexion Therapeutics Corporation$8,662,635
Christian Arthur Heidbreder · Indivior, Inc.$8,483,680
James Jeffrey Sahn · 4e Therapeutics Inc.$7,126,294

Research focus

AnalgesicsAstrocytesBaseBenchmarkingBiological MarkersBiological SciencesCell LineCell LineageCellsClassificationData AnalysesDesignDopaminergic NeuronDrug DiscoveryDrug TargetingEconomic BurdenElectrophysiology (Science)Emergency SituationEngineeringExpression VectorGene ExpressionGene Expression AlterationGene Expression ProfilingAddiction

Grant awards (1)

High-throughput profiling of compound abuse liabilities and identification of addiction-related drug targets using an iPSC-enabled platform$323,750

R44 · FY2019 · DA · contact PI